据了解，*ST生物原拟收购程泽能、易木林、长沙君合致远企业管理咨询合伙企业（有限合伙）、长沙 市履方医药信息咨询合伙企业（有限合伙）合计持有的湖南慧泽生物医药科技有限公司51%股权。 *ST生物表示，自筹划重大资产重组事项以来，公司按照相关法律法规要求，积极推进本次重大资产重 组的各项工作。交易各方对本次重大资产重组交易方案进行了多次协商和谈判，未能最终达成一致。为 切实维护公司及全体股东利益，经公司审慎研究，并与交易各方友好协商，交易各方一致同意终止筹划 本次交易。 北京商报讯（记者 丁宁）1月22日晚间，*ST生物（000504）发布公告称，公司于2025年8月12日披露了 《关于筹划重大资产重组暨签署股权收购意向协议的提示性公告》，本次筹划重组事项尚未进入正式实 施阶段，交易各方未达成实质性协议，1月22日公司与交易各方签署了《股权收购意向协议之终止协 议》。 ...

Core Viewpoint - *ST Bio (000504.SZ) is expected to achieve a net profit attributable to shareholders of 28.5 million to 32.5 million yuan in 2025, marking a turnaround from loss to profit compared to the previous year [1] Group 1: Financial Performance - The company anticipates a net profit of 8.5 million to 12.5 million yuan after deducting non-recurring gains and losses, also indicating a turnaround from loss to profit year-on-year [1] - Projected operating revenue is between 385 million to 425 million yuan [1] Group 2: Business Development - During the reporting period, the company acquired and took control of Loudi Jinhong New Materials Co., Ltd., which significantly enhanced its revenue from the recycling of resources such as waste power batteries and scrap steel [1] - The company has actively expanded sales of related derivative products in its main business, including beauty products and health supplements related to the biopharmaceutical sector, contributing to revenue and profit growth [1] Group 3: Cost Management - The company improved its profitability through measures such as organizational restructuring, personnel optimization, and cost control [1] - Government subsidies received during the reporting period increased compared to the previous year [1]

格隆汇1月22日丨*ST生物（维权）(000504.SZ)公布，公司于2025年8月12日披露了《关于筹划重大资产 重组暨签署股权收购意向协议的提示性公告》（公告编号：2025-047），公司拟收购程泽能、易木林、 长沙君合致远企业管理咨询合伙企业（有限合伙）、长沙市履方医药信息咨询合伙企业（有限合伙）合 计持有的湖南慧泽生物医药科技有限公司51%股权。 自筹划重大资产重组事项以来，公司按照相关法律法规要求，积极推进本次重大资产重组的各项工作。 交易各方对本次重大资产重组交易方案进行了多次协商和谈判，未能最终达成一致。为切实维护公司及 全体股东利益，经公司审慎研究，并与交易各方友好协商，交易各方一致同意终止筹划本次交易，2026 年1月22日公司与交易各方签署了《股权收购意向协议之终止协议》。 ...

Core Viewpoint - Beijing plans to invest over 1.5 billion yuan in the first batch of high-precision and cutting-edge industry development projects to support innovation and the growth of small and medium-sized enterprises [1][2] Group 1: Investment and Funding - The Beijing Municipal Bureau of Economy and Information Technology aims to release no less than 25 policy support directions and plans to invest over 1.5 billion yuan [1] - The funding will cover key industries such as integrated circuits, biomedicine, material energy, information software, and the digital economy [1] Group 2: Innovation Promotion - Beijing encourages market validation opportunities for innovative products in fields like robotics, integrated circuits, and new materials [1] - Support will be provided for the first trial applications of robotics in various domestic scenarios, including factories, supermarkets, logistics, and agriculture [1] - The initiative includes backing for the demonstration application of advanced strategic materials and commercial aerospace companies to mitigate innovation risks through insurance [1] Group 3: Transformation Support - Beijing will support the construction of pilot testing platforms and production lines, providing up to 30% of the total project investment for key technology implementation [2] - Manufacturing enterprises will receive support for introducing new products using existing production capacities, with a maximum funding of 50 million yuan [2] Group 4: Quality and Efficiency Enhancement - The initiative includes support for service providers and benchmark enterprises to offer transformation solutions for large-scale manufacturing enterprises [2] - Standards for green and low-carbon transformation of industrial production lines and data centers will be proposed [2] - Companies will be encouraged to enhance software development efficiency and intelligence through computing power construction, large model deployment, and data governance [2]

Core Insights - The Hong Kong stock market is experiencing a new wave of IPOs in early 2026, particularly in hard technology sectors, attracting significant attention from capital markets [1][3] - Wealth management companies are entering the Hong Kong IPO market as cornerstone and anchor investors, marking a new phase in their equity investment capabilities [1][3] Group 1: Investment Performance - ICBC Wealth Management reported a 100% success rate in its investments in 10 Hong Kong IPOs, with the highest single investment increasing by 165.45% [3] - The investments primarily cover sectors such as semiconductors, artificial intelligence, biomedicine, and high-end equipment [3] - Specific notable investments include a 67.90% increase in the stock of Zhaoyi Innovation, a 129.52% increase in AI pharmaceutical company Yingshi Intelligent, and a 52.17% increase in home robotics company Woan Robotics [3] Group 2: Strategic Developments - China Post Wealth Management has also participated in the Hong Kong IPO market, continuing its investment strategy that began in 2024, which has included companies like Midea Group and CATL [4] - The implementation of asset management regulations has led to a shift towards net value transformation in the banking wealth management sector, increasing investor demand for enhanced asset returns [4] - Wealth management companies are enhancing their equity investment capabilities and diversifying their product strategies through participation in Hong Kong IPOs [4] Group 3: Future Outlook - Analysts suggest that the current participation of wealth management companies in Hong Kong IPOs is still in a trial phase, but it is expected to evolve into a more institutionalized, productized, and strategic equity allocation approach in the long term [5] - There are challenges in project acquisition, research capabilities, and risk management that need to be addressed for effective participation in the IPO market [5] - Companies are encouraged to strengthen their fundamental research and valuation assessments of IPO candidates, as well as to establish comprehensive risk management mechanisms throughout the investment process [5]

Core Viewpoint - Shenzhen has launched a "State-owned Capital Fund Matrix Three-Year Action Plan" to focus on supporting hard technology sectors such as semiconductors, integrated circuits, artificial intelligence, and biomedicine [1] Group 1: Fund Matrix and Strategic Focus - The fund matrix is based on the "Shenzhen Municipal State-owned Enterprises Fund Business Management Measures (Trial)" issued on January 1, 2023, and aims to cover the entire lifecycle of enterprises from seed to maturity [1] - This initiative is expected to concentrate state-owned capital on forward-looking strategic emerging industries, enhancing the long-term guiding and amplifying role of state-owned capital in technological innovation investments [1] - The Shenzhen State-owned Assets Supervision and Administration Commission aims to link innovation elements such as technology, talent, and scenarios to empower sci-tech enterprises throughout their lifecycle [1] Group 2: Collaboration and Ecosystem Development - Shenzhen's state-owned enterprises are transitioning from "resource holders" to "ecosystem builders," collaborating with private enterprises to create a virtuous cycle of innovation [3] - The Shenzhen Capital Group has invested 86% of its funds in early-stage and growth-stage companies, nurturing 288 listed companies to date [3] - The Kunpeng Capital sub-fund group has a cumulative investment scale exceeding 100 billion, covering nearly 2,000 projects, establishing a mature operational foundation for collaborative development in the industrial chain [3] Group 3: Investment Strategies and Fund Scale - Shenzhen is promoting "bold capital" and "patient capital" from state-owned enterprises, with over 500 funds created by the end of 2024, totaling over 700 billion, with more than 90% directed towards the "20+8" industries [4] - The Shenzhen Semiconductor and Integrated Circuit Industry Investment Fund was established with an initial scale of 5 billion, focusing on investments in semiconductor equipment, components, chip design, and advanced packaging [4] - The Shenzhen State-owned Assets Supervision and Administration Commission emphasizes the importance of maintaining the function of patient capital and continuously improving fund collaboration, project cultivation, and ecological service mechanisms [4]

（记者 曾健辉） 每经AI快讯，新产业1月22日晚间发布公告称，深圳市新产业生物医学工程股份有限公司于近日收到1 项国家知识产权局、2项俄罗斯联邦知识产权局颁发的《发明专利证书》。专利名称分别为"全血样本中 待测物的免疫学检测方法、磁性微球及磁性微球-蛋白复合物中国专利号""试剂组合以及免离心的全血 中目标免疫抑制剂的检测方法"等。 每经头条（nbdtoutiao）——特朗普强要格陵兰岛，丹麦一养老基金率先清仓美债，美国资产全线下 跌！欧洲手握"金融核按钮"，双方会"鱼死网破"吗？专家解读→ ...

Core Viewpoint - China Life Overseas Company has established itself as a leading Chinese insurance company and institutional investor in the Hong Kong and Macau regions, with total assets exceeding HKD 452.8 billion, focusing on life insurance, savings insurance, annuities, and MPF [1] Group 1: Investment Strategy and Market Position - The company utilizes its long-term capital advantage for global stable asset allocation, contributing to reliable returns for clients and supporting the stability and prosperity of the local capital market [1] - As a representative of "patient capital," the investment strategy emphasizes risk management and long-term value creation, injecting strong momentum into the sustainable development of Hong Kong as an international financial center [1] - The company actively supports the Hong Kong SAR government and the Ministry of Finance of China in issuing government bonds, further consolidating the influence of the Hong Kong bond market [1] Group 2: Participation in Bond Issuance - In November 2025, the Hong Kong SAR government issued multi-currency digital green bonds, and China Life Overseas Company participated in all four currency bond subscriptions, totaling approximately HKD 2.4 billion, becoming the largest subscriber among Chinese insurance companies [1] - The Ministry of Finance of China issued USD 4 billion in 3-year and 5-year dollar bonds, with China Life Overseas Company subscribing approximately USD 600 million, showcasing its stable capital allocation advantage [2] Group 3: Support for IPOs and Innovative Sectors - In 2025, the company participated in multiple Hong Kong H-share IPOs, supporting the Stock Exchange's Chapter 18A regulations, which allow unprofitable biotech companies to list [2] - The company actively invests in hot sectors such as semiconductors, AI, and healthcare, supporting excellent Chinese enterprises in achieving reasonable pricing during IPOs [2] - Notable investments include Hesai Technology, a leader in the 3D sensor field, which became the first company to produce over 1 million laser radars by 2025 and successfully listed on the Hong Kong Stock Exchange [2] Group 4: Alternative Investment Initiatives - To deepen communication and cooperation in Hong Kong's alternative investment industry, the company successfully hosted the "Hong Kong Alternative Investment Strategy Conference" in 2025, gathering nearly 800 experts to discuss alternative investment opportunities [4] - The unique position of Hong Kong as a bridgehead provides ample space for insurance funds to explore alternative opportunities [4] - The company regularly organizes high-end investment research activities, enhancing Hong Kong's status as an international insurance and asset management hub and promoting cross-border cooperation and innovation [4]

Core Insights - The East China Normal University Asia-Europe Business School successfully held the 2025 Corporate Mentor Meet and Appointment Ceremony, officially appointing 41 industry leaders and business elites as the new corporate mentors, marking a significant step in the school's strategy of deepening industry-education integration and collaborative talent cultivation [2] Group 1: Corporate Mentor Program - The corporate mentor program, a core component of the Asia-Europe Business School's "dual mentor system," has successfully held nine sessions to date, aiming to build an efficient communication platform between students and industry leaders, integrating cutting-edge business practices with rigorous academic theories [4] - The program has gathered over 200 corporate mentors and benefited nearly 800 students, serving as an important bridge between campus and industry [4] Group 2: Participation and Industry Coverage - The current corporate mentor program attracted 163 students from 42 countries and regions, with a strong lineup of 41 industry leaders joining or continuing their roles, covering various cutting-edge sectors such as consulting, intelligent manufacturing, marketing, biomedicine, financial services, and information technology [6] - Notably, Xu Xiaopeng, a senior product and technology expert, joined the program, bringing extensive experience from leading roles at Amazon, JD.com, and Ctrip, along with multiple prestigious awards [6] Group 3: Educational Philosophy and Future Directions - The Dean of the Asia-Europe Business School emphasized the need for business education to actively adapt and innovate in the context of artificial intelligence reshaping global business logic, aiming to help students grasp three core learning dimensions: understanding fundamental business logic, deep industry-specific knowledge, and appreciating the human and life values behind business activities [8] - The project director highlighted the corporate mentor program as a key link between academia and the business world, providing students with insights into the real business environment and continuously supplying companies with future leaders possessing international perspectives and excellent professional qualities [10] Group 4: Interactive Engagement - Following the ceremony, students engaged in deep discussions with their mentors across six industry sub-forums, focusing on topics such as industry trends, career development paths, core competency building, and internship opportunities [11] - The Asia-Europe Business School views the corporate mentor program as a strategic initiative to deepen industry-education integration and ensure precise alignment between talent cultivation and industry needs, with plans to continuously invest resources and optimize the program's operations and interaction mechanisms [11]

Core Viewpoint - The company, 心玮医疗-B (06609), announced a share buyback plan, indicating a strategic move to enhance shareholder value through the repurchase of shares [1] Group 1 - The company will spend HKD 2.243 million to repurchase 40,000 shares [1]